103 related articles for article (PubMed ID: 8624757)
1. The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine.
LaCasse RA; Remington KM; North TW
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 May; 12(1):26-32. PubMed ID: 8624757
[TBL] [Abstract][Full Text] [Related]
2. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Gobert JM; Remington KM; Zhu YQ; North TW
Antimicrob Agents Chemother; 1994 Apr; 38(4):861-4. PubMed ID: 8031060
[TBL] [Abstract][Full Text] [Related]
3. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
Medlin HK; Zhu YQ; Remington KM; Phillips TR; North TW
Antimicrob Agents Chemother; 1996 Apr; 40(4):953-7. PubMed ID: 8849258
[TBL] [Abstract][Full Text] [Related]
4. Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.
Remington KM; Chesebro B; Wehrly K; Pedersen NC; North TW
J Virol; 1991 Jan; 65(1):308-12. PubMed ID: 1845891
[TBL] [Abstract][Full Text] [Related]
5. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
[TBL] [Abstract][Full Text] [Related]
6. Reduced provirus burden and enhanced humoral immune function in AZT-treated SCID-feline mice inoculated with feline immunodeficiency virus.
Johnson CM; Selleseth DW; Ellis MN; Childers TA; Tompkins MB; Tompkins WA
Vet Immunol Immunopathol; 1995 May; 46(1-2):169-80. PubMed ID: 7618256
[TBL] [Abstract][Full Text] [Related]
7. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro.
Tanabe-Tochikura A; Tochikura TS; Blakeslee JR; Olsen RG; Mathes LE
Antiviral Res; 1992 Aug; 19(2):161-72. PubMed ID: 1332602
[TBL] [Abstract][Full Text] [Related]
8. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Palmer S; Harmenberg J; Cox S
Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486
[TBL] [Abstract][Full Text] [Related]
9. Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase.
Remington KM; Zhu YQ; Phillips TR; North TW
J Virol; 1994 Feb; 68(2):632-7. PubMed ID: 7507182
[TBL] [Abstract][Full Text] [Related]
10. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
[TBL] [Abstract][Full Text] [Related]
11. Testing of nucleoside analogues in cats infected with feline leukemia virus: a model.
Tavares L; Roneker C; Postie L; de Noronha F
Intervirology; 1989; 30 Suppl 1():26-35. PubMed ID: 2540111
[TBL] [Abstract][Full Text] [Related]
12. Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells.
Mukherji E; Au JL; Mathes LE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1573-9. PubMed ID: 7526781
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
Spector SA; Ripley D; Hsia K
Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
[TBL] [Abstract][Full Text] [Related]
14. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Connell EV; Hsu MC; Richman DD
Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
[TBL] [Abstract][Full Text] [Related]
15. Effect of 3'azido-2',3'-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats.
Smyth NR; Bennett M; Gaskell RM; McCracken CM; Hart CA; Howe JL
Res Vet Sci; 1994 Sep; 57(2):220-4. PubMed ID: 7817010
[TBL] [Abstract][Full Text] [Related]
16. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms.
Hartmann K; Donath A; Beer B; Egberink HF; Horzinek MC; Lutz H; Hoffmann-Fezer G; Thum I; Thefeld S
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):167-75. PubMed ID: 1363008
[TBL] [Abstract][Full Text] [Related]
17. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
Smith RA; Remington KM; Lloyd RM; Schinazi RF; North TW
J Virol; 1997 Mar; 71(3):2357-62. PubMed ID: 9032372
[TBL] [Abstract][Full Text] [Related]
18. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
19. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
Wondimu Z; Sönnerborg A; Ayehunie S; Britton S; Strannegård O
Antiviral Res; 1992 Oct; 19(4):353-9. PubMed ID: 1281393
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of anti-HIV nucleosides in microswine.
Swagler AR; Qian MX; Gallo JM
J Pharm Pharmacol; 1991 Dec; 43(12):823-6. PubMed ID: 1687578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
